KLK3 and neoplasm: Lm vaccines against the tumor antigens HER260 and PSA (prostate-specific antigen)61 generate potent antitumor immunity, while Lm vaccines against other tumor antigens including PAP (prostatic acid phosphatase)10 and mesothelin43 exhibited limited immunogenicity.